Journal of Nanomaterials & Molecular NanotechnologyISSN: 2324-8777

Reach Us +44-7480-724769
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Crossing the Blood-Brain Barrier with Antibody-Labeled, Gold-Coated Nanoconjugates: A Preliminary Step in Targeting and Eradicating Brain Tumors

Crossing the Blood-Brain Barrier with Antibody-Labeled, Gold-Coated Nanoconjugates: A Preliminary Step in Targeting and Eradicating Brain Tumors

This paper shows ultrastructural proof of principle that antibodylabeled nanoconjugates can cross the blood-brain barrier and bind to their targeted antigens. Gold-coated nanoconjugates labeled with monoclonal antibodies targeting brain antigens-specifically, the synaptophysin and glial fibrillary acidic proteins-were injected intravascularly into 45 Balb/c mice. Through electron microscopy a portion of the nanoconjugates were shown to have crossed the blood-brain barrier and become localized either on the intermediate filaments in the astrocytic cytoplasm (anti-glial fibrillary acidic proteins) or presynaptic membranes (anti-synaptophysin). Three of the authors have already reported on a similar and successful use of radioactive nanoconjugates to target antigens in a syngeneic murine lung tumor model using CMT-6 breast cancer cells. This proof of principle supported by concrete evidence does not include an analysis of the mechanism by which the nanoconjugates crossed the blood-brain barrier. The success of targeting proteins in the brain and, by implication, antigens in brain tumors, has immense potential for the treatment of a wide variety of metastases and tumors, including brain cancers such as glioblastoma.

Special Features

Full Text

View

Track Your Manuscript

Share This Page

Media Partners

Associations